Balyasny Asset Management
IRD

Balyasny Asset Management’s Opus Genetics IRD Stock Holding History

Balyasny Asset Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$12.4M Hold
2,718,029
– – 0.02% 936
2025
Q4 		$5.46M Buy
+2,718,029
New +$5.52M 0.01% 1351

Other funds holding IRD

CP
Caligan Partners New York $1.5B AUM 518.95% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Balyasny Asset Management's IRD Position: Q1 2026 in Review

Balyasny Asset Management held its Opus Genetics (IRD) position steady in Q1 2026 at 2,718,029 shares worth $12.4M. The position accounts for 0.02% of the portfolio, ranked #936.

Balyasny Asset Management first reported a position in IRD in Q4 2025 and has held it in 2 quarters since. 79 funds tracked by Wall St. Rank hold IRD as of Q1 2026.

  • Balyasny Asset Management held 2,718,029 shares of Opus Genetics worth $12.4M as of Q1 2026.
  • Balyasny Asset Management left its Opus Genetics share count unchanged in Q1 2026.
  • Opus Genetics made up 0.02% of Balyasny Asset Management's portfolio in Q1 2026, its #936 holding.
  • Balyasny Asset Management first reported a position in Opus Genetics in Q4 2025 and has held it in 2 quarters since.
  • 79 funds tracked by Wall St. Rank held Opus Genetics as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.